Unknown

Dataset Information

0

Flubendazole inhibits PD-1 and suppresses melanoma growth in immunocompetent mice.


ABSTRACT:

Background

Immune checkpoint inhibitor therapy has revolutionized the clinical management of a diverse range of cancer types, including advanced cutaneous melanoma. While immunotherapy targeting the PD-1/PD-L1 system has become standard of care, overall response rates remain unsatisfactory for most patients and there are no approved small molecule inhibitors of the PD-1/PD-L1 system. Flubendazole (FLU) is an anthelmintic that has been used to treat worm infections in humans and animals for decades.

Methods

Here we tested the anti-cancer activity of systemically delivered FLU with suppression of PD-1 in immunocompetent mice.

Results

In C57BL/6J mice bearing subcutaneous B16F10 melanoma, FLU reduced both tumor growth and PD-1 protein levels without affecting levels of PD-L1. FLU's suppression of PD-1 was accompanied by increased CD3+ T cell infiltration. Western blotting with extracts from human Jurkat T cells showed that FLU inhibited PD-1 protein expression, findings confirmed by flow cytometry. To gain mechanistic insights on FLU's ability to suppress PD-1 protein levels, we performed bulk RNA sequencing on extracts of Jurkat T cells exposed to the benzimidazole for 4 h. From a pool of 14,475 genes there were 1218 differentially-expressed genes; 687 with increased expression and 531 with decreased expression. Among the genes induced by FLU was the AP-1 family member, JUN and surprisingly, pdcd1. KEGG pathway analysis showed FLU up-regulated genes over-represented in multiple pathways (p < 0.01), the top hit being amoebiasis. FLU also affected the expression of genes in cancer-associated pathways, both through down-regulation and up-regulation. Gene set enrichment analysis revealed a large number of immunological signature gene sets correlated with FLU treatment, including gene sets associated with T cell differentiation, proliferation and function. The AP-1 inhibitor T5224 rescued PD-1 protein expression from inhibition by FLU.

Conclusion

This study is the first to show that FLU can inhibit melanoma growth with PD-1 suppression in immunocompetent mice.

SUBMITTER: Li Y 

PROVIDER: S-EPMC10349441 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

Flubendazole inhibits PD-1 and suppresses melanoma growth in immunocompetent mice.

Li Yue Y   Wu Ben B   Hossain Md Jakir MJ   Quagliata Lily L   O'Meara Connor C   Wilkins Marc R MR   Corley Susan S   Khachigian Levon M LM  

Journal of translational medicine 20230714 1


<h4>Background</h4>Immune checkpoint inhibitor therapy has revolutionized the clinical management of a diverse range of cancer types, including advanced cutaneous melanoma. While immunotherapy targeting the PD-1/PD-L1 system has become standard of care, overall response rates remain unsatisfactory for most patients and there are no approved small molecule inhibitors of the PD-1/PD-L1 system. Flubendazole (FLU) is an anthelmintic that has been used to treat worm infections in humans and animals f  ...[more]

Similar Datasets

| S-EPMC8741604 | biostudies-literature
| S-EPMC3308985 | biostudies-literature
| S-EPMC4632290 | biostudies-other
2025-03-02 | GSE197791 | GEO
| S-EPMC6025205 | biostudies-literature
| S-EPMC9257138 | biostudies-literature
| S-EPMC9339485 | biostudies-literature
| S-EPMC8268443 | biostudies-literature
| S-EPMC9204894 | biostudies-literature
| S-EPMC5826859 | biostudies-literature